AI Shows Promise in Predicting Breast Cancer Recurrence After DCIS Treatment

A new study suggests that artificial intelligence (AI) can effectively predict the risk of breast cancer recurrence following treatment for ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer. The AI system, analyzing preoperative mammograms, demonstrated predictive performance comparable to established clinical risk models.

Understanding DCIS and the Need for Improved Prediction

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancers detected through screening ¹. It’s characterized by the presence of cancer cells within the milk ducts, and while not immediately life-threatening, DCIS carries a risk of progressing to invasive breast cancer. Around nine out of every 1,000 women diagnosed with DCIS will develop invasive breast cancer each year ¹.

How the AI System Works

Researchers evaluated a commercially available AI system designed for breast cancer detection and diagnosis. The system analyzed preoperative mammograms from over 1,700 patients (average age 55) who underwent surgery for DCIS between January 2012 and December 2017 ³. Medical records were then analyzed to identify instances of second breast cancers.

Key Findings of the Study

The study, published in AJR in February 2026, revealed that an AI score of 73.5% or higher was significantly associated with post-breast-conserving surgery (BCS) ipsilateral recurrence at both 5 and 10 years ³. Importantly, the AI’s predictions were statistically equivalent to those generated by existing clinical models, such as the Van Nuys Prognostic Index (VNPI) and the MSKCC nomogram.

Specifically, recurrence rates observed were as follows:

• 28 women experienced post-BCS ipsilateral recurrence.
• 7 women developed post-mastectomy ipsilateral recurrence.
• 25 women developed contralateral breast cancer.

The Role of AI in Breast Cancer Management

AI is increasingly being explored for its potential to enhance various aspects of breast cancer management, including detection, diagnosis, prognosis, and treatment response prediction ¹. Beyond risk prediction, AI is as well showing promise in improving diagnostic accuracy in breast MRI ¹.

Limitations and Future Directions

While promising, it’s important to note that some research indicates current AI tools may overlook up to one in three cancers, particularly in women with dense breast tissue or smaller tumors ¹. Researchers emphasize that AI scores derived from preoperative mammography could potentially refine treatment and surveillance strategies for DCIS patients ³. Further validation and broader implementation are needed to fully realize the benefits of AI in DCIS management.

Key Takeaways

• AI can predict DCIS recurrence risk with accuracy comparable to existing clinical models.
• The AI system analyzes preoperative mammograms, offering a non-invasive assessment.
• AI has the potential to personalize treatment decisions and improve patient outcomes.
• Ongoing research is crucial to address limitations and ensure equitable access to AI-powered tools.

References

1. Yoon JH et al. Commercially available artificial intelligence score on preoperative mammography for prediction of future breast cancer after DCIS treatment. AJR. 2026;DOI:10.2214/AJR.25.34364.
2. National Health Service (NHS) England. Ductal carcinoma in situ (DCIS) data story. 2023. Available at: Last accessed 18 February 2026.
3. Artificial intelligence for breast cancer management – Nature
4. Invasion prediction with artificial intelligence in ductal…